Key points
- Same ingredient does not mean same product.
- Different trials cannot be reduced to an unqualified winner.
- Coverage follows the exact product and criteria.
Same-ingredient comparisons
Ozempic vs Wegovy separates two semaglutide products. Product indication and instructions—not ingredient alone—explain the boundary.
The liraglutide guide performs the same ingredient/product separation for Saxenda and Victoza without creating a thin comparison page.
Different-ingredient comparisons
Mounjaro vs Ozempic compares two diabetes product contexts. Mounjaro vs Wegovy shows why a popular cross-indication comparison needs extra care.
A decision matrix for choosing the right comparison
Use the treatment question to choose the document, then verify every product-level claim against the current Canadian monograph and exact DIN. Monitoring needs and individual suitability require a prescriber; access and coverage require separate checks.[5][6][7]
| Dimension | What to verify |
|---|---|
| Ingredient and class | Exact active ingredient and receptor class; do not inherit claims across classes |
| Authorized use | Current product-specific Canadian indication and any conditions |
| Route and frequency | Exact formulation and schedule; never infer dose conversion |
| Evidence and monitoring | Relevant population, outcome, duration, warnings and follow-up |
| Access | Exact DIN lifecycle and current pharmacy stock as separate facts |
| Cost and coverage | Current pharmacy quote and exact payer criteria for the prescribed DIN |
How to read any comparison
Check whether populations, indications, outcomes and study designs actually align. Then return to the Canadian monographs, individual clinical assessment and exact plan rules. Never use a comparison table as a dose-conversion or switching instruction.
Sources
- Ozempic (semaglutide injection) Product MonographHealth Canada / Novo Nordisk Canada · Checked August 14, 2026
- Wegovy (semaglutide injection) Product MonographHealth Canada / Novo Nordisk Canada · Checked August 14, 2026
- Mounjaro (tirzepatide injection) Product MonographHealth Canada / Eli Lilly Canada · Checked August 14, 2026
- Zepbound (tirzepatide injection) Product MonographHealth Canada / Eli Lilly Canada · Checked August 14, 2026
- Drug Product DatabaseHealth Canada · Checked August 14, 2026
- Drug Product Database terminologyHealth Canada · Checked August 14, 2026
- Understanding health insuranceFinancial Consumer Agency of Canada · Checked August 14, 2026